Contact Us
Dedicated to the development of an innovative, safe and effective cancer therapy based on liposome delivery
Innovative anti-cancer drug, reduced toxicity, improved efficacy using a well-established pegylated liposomal delivery system.
Clinical study being conducted for the treatment of different types of solid tumors.
This project has received funding from the European Union’s Horizon 2020 SME-Instrument program under grant agreement No 876666 — Promitil.